$5.67
+1.5%Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Moderate margins typical of competitive industries. Monitor for pricing pressure or rising costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
LFCR โข NASDAQ
| Lifecore Biomedical, Inc. Income Statement | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 | May 2019 | May 2018 | May 2017 | May 2016 | May 2015 | May 2014 | May 2013 | May 2012 | May 2011 | May 2010 | May 2009 | May 2008 | May 2007 | May 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
128.9M | 128.3M | 103.3M | 111.3M | 100.9M | 590.4M | 557.6M | 524.2M | 532.3M | 541.1M | 539.3M | 476.8M | 441.7M | 317.6M | 276.7M | 238.2M | 235.9M | 238.5M | 210.5M | 232M | |
GROSS PROFIT | ||||||||||||||||||||
(88.6M) | (86.4M) | (75.3M) | (72.2M) | (61.9M) | (515.4M) | (476.6M) | (445.9M) | (449.1M) | (470.1M) | (473.9M) | (414.2M) | (378.9M) | (265.4M) | (230M) | (204.5M) | (201.7M) | (200.3M) | (178.1M) | (191.9M) | |
40.3M | 41.9M | 28M | 39.1M | 38.9M | 75M | 81M | 78.3M | 83.2M | 71M | 65.4M | 62.6M | 62.8M | 52.1M | 46.7M | 33.8M | 34.3M | 38.2M | 32.4M | 40M | |
OPERATING INCOME | ||||||||||||||||||||
(57.5M) | (50.7M) | (49.8M) | (50.9M) | (47.8M) | (83.3M) | (75.5M) | (64.8M) | (67.7M) | (56.7M) | (46.9M) | (42.4M) | (37.9M) | (36.1M) | (33.9M) | (22.1M) | (21.7M) | (23.1M) | (2M) | (31M) | |
(44M) | (40.5M) | (39M) | (34.7M) | (27.7M) | (72.2M) | (64.1M) | (52M) | (58.2M) | (49.5M) | (40M) | (35.2M) | (32.5M) | (26.5M) | (24.6M) | (17.7M) | (18M) | (19.8M) | (21.6M) | (28M) | |
(8.3M) | (8.6M) | (8.7M) | (7.8M) | (6.7M) | (11.1M) | (11.5M) | (12.8M) | (9.5M) | (7.2M) | (7M) | (7.2M) | (9.3M) | (9.6M) | (9.3M) | (4.4M) | (3.7M) | (3.3M) | (3.1M) | (3M) | |
-17.2M | -8.8M | -21.8M | -11.8M | -8.8M | -8.3M | -8M | 11.8M | 15.5M | -19.8M | 18.5M | 20.2M | 24.9M | 14.6M | 8M | 11.7M | 12.6M | 15.2M | 30.4M | 9M | |
PRE-TAX INCOME | ||||||||||||||||||||
(21.8M) | (18.1M) | (17.6M) | (15.6M) | (8.9M) | (4.6M) | (5.2M) | (2M) | (1.8M) | (2M) | (1.8M) | (1.7M) | (2M) | (929K) | (820K) | (88K) | (8K) | (0.0) | (0.0) | (0.0) | |
-21.8M | -18.1M | -17.6M | -15.5M | -8.9M | -4.6M | -5.1M | -1.7M | -1.8M | -1.9M | -1.5M | -1.4M | -1.8M | -749K | -390K | 746K | 1.3M | 0.0 | 0.0 | 0.0 | |
(5.2M) | (1.7M) | (2.1M) | (8.4M) | (13.4M) | (0.0) | (0.0) | (0.0) | -333K | (0.0) | (0.0) | (0.0) | (8.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -22.7M | (0.0) | |
-21.4M | 18.4M | -42.1M | -8.9M | -21M | -4.8M | -1.8M | 2.8M | -493K | 934K | 3M | 9.7M | 7.4M | 5.7M | 410K | 746K | 743K | 2.2M | 1.7M | -24K | |
-38.7M | 9.5M | -63.9M | -20.7M | -29.8M | -51.3M | 3.6M | 16.4M | 15M | -18.9M | 21.5M | 29.9M | 32.3M | 20.3M | 8.4M | 8.7M | 13.3M | 16.9M | 31.6M | 9M | |
NET INCOME | ||||||||||||||||||||
(43K) | (183K) | (308K) | -5.2M | -6.4M | -13.1M | (1.5M) | -9.4M | (4.3M) | -7.4M | (7.7M) | (10.6M) | (9.5M) | (7.2M) | (4.2M) | (4.3M) | (5.6M) | (3.4M) | (2.5M) | (396K) | |
-38.7M | 12M | -99.6M | -116.7M | -32.3M | -38.2M | 2.1M | 24.8M | 10.6M | -11.6M | 13.5M | 19.1M | 22.6M | 12.7M | 3.9M | 4M | 7.7M | 13.5M | 29.2M | 8.7M |
LFCR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 14, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 17, 2025 | November 17, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 31, 2025 | October 29, 2025 | 2025 |
Continue your LFCR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.